Phase 2 Mesothelioma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People of Asian ethnicity, aged between 18 and 75, who are generally able to carry out normal daily activities with little or no restriction (confirm with trial site regarding the activity level assessment)
• People who have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs) confirmed by laboratory tissue testing
• People whose cancer has continued to grow or spread after receiving at least one but no more than two previous treatments, such as platinum-based chemotherapy, immunotherapy combinations, or anti-blood-vessel-growth (anti-angiogenic) therapy
• People who have at least one area of cancer that can be measured on scans, according to a specific medical measurement standard
• People whose blood counts and kidney function meet minimum levels set by the trial (confirm with trial site for exact blood test requirements)

Who may not be able to join:

• People who have had another type of cancer within the past 5 years, with some exceptions for certain fully treated skin cancers or early-stage cancers that were completely removed (confirm with trial site for details)
• People whose tumour is found on scans to be wrapping around major blood vessels, or showing signs of breakdown or cavity formation that could cause significant bleeding, as assessed by the trial doctor
• People whose tumour has grown into nearby vital organs or blood vessels such as the heart, windpipe, food pipe, or major arteries, or where there is a risk of abnormal tunnels forming between these structures
• People who are currently taking part in another interventional clinical trial, or who have received an experimental drug or device within the 4 weeks before starting the trial
• People who have received certain local treatments to non-target areas of cancer within 2 weeks before starting, or certain immune-boosting treatments within 2 weeks, or herbal or traditional Chinese medicines with anti-cancer properties within 1 week before starting
• People who have previously received a combination of anti-blood-vessel-growth therapy together with certain immunotherapy drugs (PD-1 or PD-L1 inhibitors), including drugs such as bevacizumab or similar medicines
• People who have had a serious bleeding event (graded as severe or higher) within the 4 weeks before screening, or who have had a solid organ or bone marrow transplant at any time
• People with active uncontrolled infections such as acute pneumonia, or a flare-up of a chronic lung condition, within the past month, or active tuberculosis
• People with certain ongoing lung conditions such as idiopathic pulmonary fibrosis, organising pneumonia, or lung inflammation caused by medication
• People who have had major surgery or serious injury within 30 days before starting the trial, or who are expected to need major surgery within 30 days after starting; or who have had a minor procedure (other than certain port insertions) within 3 days before starting
• People with a history of serious heart muscle disease, dangerous heart rhythm problems, a recent heart attack, unstable chest pain, or significant heart failure within the past 12 months
• People with high blood pressure that cannot be controlled with medication (at or above 150/100 mmHg), or who have had a severe high blood pressure crisis
• People with active cancer spread to the brain or the membranes surrounding the brain and spinal cord, except for brain metastases that are not causing symptoms
• People with active bleeding in the digestive system, active stomach or bowel ulcers, or conditions that pose a risk of bowel perforation
• People with active autoimmune diseases that have required treatment with immune-suppressing medications or steroids within the past 2 years (replacement therapies such as thyroid hormone or insulin are generally allowed)
• People who require ongoing daily use of corticosteroid tablets above a certain dose (equivalent to more than 10 mg of prednisone per day); inhaled or topical steroids for asthma or skin conditions are generally allowed
• People with wounds that are not healing or fractures that have not healed
• People with a known allergy or severe reaction to any component of the study drugs, or a history of severe reactions to monoclonal antibody treatments
• Women who are not surgically sterilised, not past menopause, or unwilling to use contraception during treatment and for 6 months afterwards; women who are pregnant or breastfeeding
• Men who are not surgically sterilised or who are unwilling to use contraception during treatment and for 6 months afterwards
• People who are HIV positive
• People with active hepatitis B where the virus levels in the blood are above a certain threshold; people with lower virus levels may be eligible only if they receive antiviral treatment throughout the study
• People with active hepatitis C infection confirmed by blood tests
• People with substance use issues or psychiatric conditions that may affect their ability to follow the trial requirements
• People who have received a live vaccine within 30 days before starting the trial (inactivated vaccines are generally allowed)
• People with any other condition that the trial doctor considers may interfere with the trial results or is not in the person's best interest to participate

Important: Always verify eligibility with the trial site directly before applying.